Cons: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy?

Treating medically inoperable patients with T2N0 NSCLC central in the lung hilus by stereotactic body radiation therapy (SBRT) is a promising treatment option. Unfortunately, solid dose and volume related toxicity data are presently lacking, so that risk estimation for severe toxicities is difficult, while we simultaneously do not have evidence that such treatment would be more effective compared to conventional fractionated radiotherapy.